Sinco Pharmaceuticals Holdings Ltd. (HK:6833)
:6833
Want to see HK:6833 full AI Analyst Report?
6833 Stock Chart & Stats
HK$0.18
HK$0.02(7.44%)
At close: 4:00 PM EST
HK$0.18
HK$0.02(7.44%)
Day’s Range― - ―
52-Week RangeHK$0.15 - HK$0.28
Previous CloseN/A
Volume2.13M
Average Volume (3M)210.00K
Market Cap
HK$384.22M
Enterprise ValueHK$149.01M
Total Cash (Recent Filing)HK$374.53M
Total Debt (Recent Filing)HK$183.47M
Price to Earnings (P/E)9.5
Beta0.20
Next Earnings
Sep 02, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend Yield1.12%
Share Statistics
EPS (TTM)0.01
Shares Outstanding2,032,890,600
10 Day Avg. Volume85,200
30 Day Avg. Volume210,000
Financial Highlights & Ratios
PEG Ratio-0.49
Price to Book (P/B)0.47
Price to Sales (P/S)0.16
P/FCF Ratio2.02
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Improving Balance SheetDebt-to-equity falling to ~0.26 from ~0.53 signals materially lower leverage and improved solvency. That provides durable financial flexibility across the next several quarters to absorb shocks, finance targeted capex or working-capital needs and reduce refinancing risk without altering core operations.
Cash-flow ReboundA return to positive OCF (~169M) and FCF (~160M) improves near-term liquidity and internal funding capacity. Sustained cash conversion enables consistent supplier and payroll funding, supports modest reinvestment or deleveraging, and materially reduces dependency on external financing over the coming months.
Consistent Positive Net IncomeMaintaining positive net income despite pressure indicates the business still generates basic earnings and can fund day-to-day operations. This steadiness preserves the company's ability to meet obligations, support modest shareholder returns, and plan investments without immediate structural overhaul.
Bears Say
Sharp Revenue DeclineAn ~18% revenue drop reverses prior growth and reduces operating scale, which can erode bargaining power and fixed-cost absorption. Persistent top-line contraction over several quarters would strain margins, capex plans and growth initiatives, making recovery and strategic investment harder over months.
Structurally Thin MarginsCompressed gross and operating margins leave little buffer against cost inflation or revenue shocks. With net margin near 1.7% and ROE muted, the firm has constrained internal capital for R&D, marketing or reserve building, increasing vulnerability to adverse industry or input-cost changes over the medium term.
Volatile Cash GenerationHistorical swings and a prior year of negative free cash flow signal execution and working-capital risk. Volatility undermines reliable planning for capex, dividends or debt paydowns and raises the chance that future adverse quarters could force external financing or cutbacks, impacting strategic options.
Sinco Pharmaceuticals Holdings Ltd. News
6833 FAQ
What was Sinco Pharmaceuticals Holdings Ltd.’s price range in the past 12 months?
Sinco Pharmaceuticals Holdings Ltd. lowest stock price was HK$0.15 and its highest was HK$0.28 in the past 12 months.
What is Sinco Pharmaceuticals Holdings Ltd.’s market cap?
Sinco Pharmaceuticals Holdings Ltd.’s market cap is HK$384.22M.
When is Sinco Pharmaceuticals Holdings Ltd.’s upcoming earnings report date?
Sinco Pharmaceuticals Holdings Ltd.’s upcoming earnings report date is Sep 02, 2026 which is in 120 days.
How were Sinco Pharmaceuticals Holdings Ltd.’s earnings last quarter?
Sinco Pharmaceuticals Holdings Ltd. released its earnings results on Mar 26, 2026. The company reported HK$0.006 earnings per share for the quarter, beating the consensus estimate of N/A by HK$0.006.
Is Sinco Pharmaceuticals Holdings Ltd. overvalued?
According to Wall Street analysts Sinco Pharmaceuticals Holdings Ltd.’s price is currently Overvalued.
Does Sinco Pharmaceuticals Holdings Ltd. pay dividends?
Sinco Pharmaceuticals Holdings Ltd. pays a Annually dividend of HK$0.002 which represents an annual dividend yield of 1.12%. See more information on Sinco Pharmaceuticals Holdings Ltd. dividends here
What is Sinco Pharmaceuticals Holdings Ltd.’s EPS estimate?
Sinco Pharmaceuticals Holdings Ltd.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Sinco Pharmaceuticals Holdings Ltd. have?
Sinco Pharmaceuticals Holdings Ltd. has 2,032,890,600 shares outstanding.
What happened to Sinco Pharmaceuticals Holdings Ltd.’s price movement after its last earnings report?
Sinco Pharmaceuticals Holdings Ltd. reported an EPS of HK$0.006 in its last earnings report, beating expectations of N/A. Following the earnings report the stock price went up 2.299%.
Which hedge fund is a major shareholder of Sinco Pharmaceuticals Holdings Ltd.?
Currently, no hedge funds are holding shares in HK:6833
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Sinco Pharmaceuticals Holdings Ltd. Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Negative
20 days / 200 days
Momentum
-21.16%
12-Months-Change
Fundamentals
Return on Equity
5.03%
Trailing 12-Months
Asset Growth
-3.37%
Trailing 12-Months
Company Description
Sinco Pharmaceuticals Holdings Ltd.
Sinco Pharmaceuticals Holdings Limited, an investment holding company, provides marketing, promotion, and channel management services for imported pharmaceutical products and medical devices in China. The company offers Octapharma, a human albumin solution for use in premature infants; Axetine, which is used for the treatment of bacterial infections, including respiratory infections, urinary tract infections, soft tissue infections, gynecological and obstetrical infections, gonorrhea, and other infections, as well as for the prevention of post-surgery infections; and Medocef that is used for the treatment of bacterial infections, such as the infections of the lower respiratory tract comprising pneumonia, urinary tract, bile duct, peritoneum, skin, soft tissue, pelvic area, and sepsis. It also provides Esafosfina, which is used for treating hypophosphatemia and chronic diseases, including alcohol intoxication, malnutrition, and hypophosphatemic respiratory failure; Taurolite, a third generation oral cholic acid drug that is used for the treatment of gallstone diseases; and Tamifil injection for the treatment of metastatic prostate cancer, true precocious puberty, and endometriosis. In addition, the company engages in the sale of pharmaceutical products; and provides warehouse facilities for pharmaceutical products; and offers international trade services, as well as provides consultation services for medical and biological technology. The company was founded in 2011 and is headquartered in Chengdu, the People's Republic of China. Sinco Pharmaceuticals Holdings Limited is a subsidiary of Risun Investments Limited.
Technical Analysis
Wanka Online, Inc.
―
Asiaray Media Group Ltd.
―
SEEC Media Group Limited
―
Netjoy Holdings Limited
―
Rego Interactive Co., Ltd.
―